<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01060020</url>
  </required_header>
  <id_info>
    <org_study_id>09-1780</org_study_id>
    <nct_id>NCT01060020</nct_id>
  </id_info>
  <brief_title>Acute Hemodynamic Effects of Sildenafil in Patients With Severe Aortic Stenosis</brief_title>
  <official_title>Acute Hemodynamic Effects of Sildenafil in Patients With Severe Aortic Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Barnes-Jewish Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary hypertension is common in patients with aortic stenosis and is associated with
      worse operative and long-term outcomes. Sildenafil has been shown to reduce pulmonary artery
      pressure and improve exercise performance in patients with left-sided heart failure, but this
      has not been tested in patients with aortic stenosis. We hypothesize that Sildenafil will
      produce a clinically significant decrease in pulmonary artery pressure in patients with
      severe aortic stenosis. The dose of Sildenafil that produces a significant decrease in
      pulmonary artery pressure will be safe and well tolerated in patients with and without a
      depressed ejection fraction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with severe aortic stenosis referred for a clinically ordered right and left heart
      catheterization will be eligible. Twenty subjects will be enrolled: 10 patients will receive
      40mg and 10 patients will receive 80mg; each dose will be equally distributed among those
      with preserved (≥50%) and reduced (&lt;50%) EF. Subjects will get a baseline echo prior to the
      heart catheterization. Baseline invasive hemodynamic measurements will be performed using a
      Swan Ganz catheter. A single oral dose of sildenafil will then be administered (40mg or
      80mg), followed by invasive hemodynamic measurements at 30 and 60 minutes. Also at 60
      minutes, limited echocardiographic images will be obtained.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Mean Pulmonary Artery Pressure in the Whole Cohort.</measure>
    <time_frame>Baseline and 60 minutes after drug administered</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Pulmonary Vascular Resistance in the Whole Cohort.</measure>
    <time_frame>Baseline and 60 minutes after drug administered</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Cardiac Index.</measure>
    <time_frame>Baseline and 60 minutes after drug administered</time_frame>
    <description>Cardiac index is cardiac output divided by body surface area.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Load Independent Index of Diastolic Filling.</measure>
    <time_frame>Baseline and 60 minutes after drug administered</time_frame>
    <description>Measurements of the load independent index of diastolic filling were made with the parameterized diastolic filling formalism as previously described and validated with the use of transmitral Doppler E waves recorded during different respiratory states (regular breathing and held expiration and inspiration).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Longitudinal Strain</measure>
    <time_frame>Baseline and 60 minutes after drug administered</time_frame>
    <description>Global longitudinal strain was measured at baseline and 60 minutes after drug administration.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Sildenafil 40mg or 80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of Sildenafil (either 40mg or 80mg) will be administered to a participant after baseline hemodynamics are measured in the catheterization lab. Each dose will be equally distributed among those with preserved (≥50%) and reduced (&lt;50%) EF.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>Single oral dose of 40mg or 80mg of Sildenafil</description>
    <arm_group_label>Sildenafil 40mg or 80mg</arm_group_label>
    <other_name>Revatio</other_name>
    <other_name>Viagra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe aortic stenosis (AVA &lt; 1.0 cm2)

          -  Referred for a clinically ordered right and left heart catheterization

          -  18 years of age and older

          -  Able and willing to comply with all requirements of the study

        Exclusion Criteria:

          -  Nitrate use within 24 hours

          -  SBP &lt; 110 mmHg or MAP &lt; 75 mmHg

          -  Severe mitral regurgitation

          -  Severe aortic regurgitation

          -  Increased risk of priapism

          -  Retinal or optic nerve problems or unexplained visual disturbance

          -  Alpha antagonists or cytochrome P450 3A4 inhibitors use within 24 hours

          -  Current or recent (≤ 30 days) acute coronary syndrome

          -  O2 sat &lt; 90% on room air

          -  Females that are pregnant or believe they may be pregnant

          -  Any condition which the PI determines will place the subject at increased risk or is
             likely to yield unreliable hemodynamic data

          -  Unwilling to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian R. Lindman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lindman BR, Zajarias A, Madrazo JA, Shah J, Gage BF, Novak E, Johnson SN, Chakinala MM, Hohn TA, Saghir M, Mann DL. Effects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosis. Circulation. 2012 May 15;125(19):2353-62. doi: 10.1161/CIRCULATIONAHA.111.081125. Epub 2012 Mar 25.</citation>
    <PMID>22447809</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2010</study_first_submitted>
  <study_first_submitted_qc>January 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2010</study_first_posted>
  <results_first_submitted>January 25, 2018</results_first_submitted>
  <results_first_submitted_qc>April 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 25, 2018</results_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Brian Lindman, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Aortic valve stenosis</keyword>
  <keyword>Sildenafil</keyword>
  <keyword>Phosphodiesterase inhibitors</keyword>
  <keyword>Hypertension, Pulmonary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants stratified according to ejection fraction and randomized to either Sildenafil 40mg and 80mg Groups were combined into a single Arm/Group for analysis as pre-specified in the study protocol.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sildenafil 40mg or 80mg</title>
          <description>A single oral dose of Sildenafil (either 40mg or 80mg) will be administered to a participant after baseline hemodynamics are measured in the catheterization lab.
Sildenafil: Single oral dose of 40mg or 80mg of Sildenafil</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sildenafil 40mg or 80mg</title>
          <description>A single oral dose of Sildenafil (either 40mg or 80mg) will be administered to a participant after baseline hemodynamics are measured in the catheterization lab.
Sildenafil: Single oral dose of 40mg or 80mg of Sildenafil</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Mean Pulmonary Artery Pressure in the Whole Cohort.</title>
        <time_frame>Baseline and 60 minutes after drug administered</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil 40mg or 80mg</title>
            <description>A single oral dose of Sildenafil (either 40mg or 80mg) will be administered to a participant after baseline hemodynamics are measured in the catheterization lab.
Sildenafil: Single oral dose of 40mg or 80mg of Sildenafil</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Mean Pulmonary Artery Pressure in the Whole Cohort.</title>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25" lower_limit="-32" upper_limit="-21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Pulmonary Vascular Resistance in the Whole Cohort.</title>
        <time_frame>Baseline and 60 minutes after drug administered</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil 40mg or 80mg</title>
            <description>A single oral dose of Sildenafil (either 40mg or 80mg) will be administered to a participant after baseline hemodynamics are measured in the catheterization lab. Each dose will be equally distributed among those with preserved (≥50%) and reduced (&lt;50%) EF.
Sildenafil: Single oral dose of 40mg or 80mg of Sildenafil</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Pulmonary Vascular Resistance in the Whole Cohort.</title>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29" lower_limit="-49" upper_limit="-13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Cardiac Index.</title>
        <description>Cardiac index is cardiac output divided by body surface area.</description>
        <time_frame>Baseline and 60 minutes after drug administered</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil 40mg or 80mg</title>
            <description>A single oral dose of Sildenafil (either 40mg or 80mg) will be administered to a participant after baseline hemodynamics are measured in the catheterization lab. Each dose will be equally distributed among those with preserved (≥50%) and reduced (&lt;50%) EF.
Sildenafil: Single oral dose of 40mg or 80mg of Sildenafil</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Cardiac Index.</title>
          <description>Cardiac index is cardiac output divided by body surface area.</description>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="-4" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Load Independent Index of Diastolic Filling.</title>
        <description>Measurements of the load independent index of diastolic filling were made with the parameterized diastolic filling formalism as previously described and validated with the use of transmitral Doppler E waves recorded during different respiratory states (regular breathing and held expiration and inspiration).</description>
        <time_frame>Baseline and 60 minutes after drug administered</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil 40mg or 80mg</title>
            <description>A single oral dose of Sildenafil (either 40mg or 80mg) will be administered to a participant after baseline hemodynamics are measured in the catheterization lab. Each dose will be equally distributed among those with preserved (≥50%) and reduced (&lt;50%) EF.
Sildenafil: Single oral dose of 40mg or 80mg of Sildenafil</description>
          </group>
        </group_list>
        <measure>
          <title>Load Independent Index of Diastolic Filling.</title>
          <description>Measurements of the load independent index of diastolic filling were made with the parameterized diastolic filling formalism as previously described and validated with the use of transmitral Doppler E waves recorded during different respiratory states (regular breathing and held expiration and inspiration).</description>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Longitudinal Strain</title>
        <description>Global longitudinal strain was measured at baseline and 60 minutes after drug administration.</description>
        <time_frame>Baseline and 60 minutes after drug administered</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil 40mg or 80mg</title>
            <description>A single oral dose of Sildenafil (either 40mg or 80mg) will be administered to a participant after baseline hemodynamics are measured in the catheterization lab. Each dose will be equally distributed among those with preserved (≥50%) and reduced (&lt;50%) EF.
Sildenafil: Single oral dose of 40mg or 80mg of Sildenafil</description>
          </group>
        </group_list>
        <measure>
          <title>Global Longitudinal Strain</title>
          <description>Global longitudinal strain was measured at baseline and 60 minutes after drug administration.</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.5" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.8" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sildenafil 40mg or 80mg</title>
          <description>A single oral dose of Sildenafil (either 40mg or 80mg) will be administered to a participant after baseline hemodynamics are measured in the catheterization lab.
Sildenafil: Single oral dose of 40mg or 80mg of Sildenafil</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>SVT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brian R. Lindman, MD, Assistant Professor of Medicine</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-747-3617</phone>
      <email>brlindman@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

